Rotating PET and linear accelerator system for PET-guided radiation therapy

用于 PET 引导放射治疗的旋转 PET 和直线加速器系统

• 批准号: 8920500
• 负责人: Samuel Mazin
• 金额: $ 26.42万
• 依托单位: REFLEXION MEDICAL, INC.
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-26 至 2017-08-01
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8920500
• 关键词: Accounting; Affect; Articular Range of Motion; Biological; Cancer Patient; Clinical; Data; Development; Diagnostic Neoplasm Staging; Disease; Dose; Effectiveness; Exhibits; Goals; Health; Image; Individual; Knowledge; Lesion; Linear Accelerator Radiotherapy Systems; Location; Lung; Malignant Neoplasms; Medical; Methods; Modality; Molecular Conformation; Motion; Movement; Neoplasm Metastasis; Normal tissue morphology; Operative Surgical Procedures; Output; Patients; Phase; Positioning Attribute; Positron-Emission Tomography; Prostate; Radiation; Radiation Scattering; Radiation therapy; Radiosurgery; Respiration; Risk; Roentgen Rays; Sensitivity and Specificity; Site; Small Business Innovation Research Grant; Solutions; Source; Staging; Structure; System; Techniques; Technology; Time; Tissues; Toxic effect; Work; base; cancer type; commercialization; data acquisition; improved; innovation; magnetic field; novel; oncology; operation; prototype; radiation effect; research study; respiratory; simulation; simulation software; success; treatment planning; tumor

DESCRIPTION (provided by applicant): Ablative radiotherapy is a very effective way to non-invasively destroy a tumor. Tumors in the body, however, move with respiration and require precise targeting for this high dose treatment. There are a variety of technologies that implement tumor tracking to achieve ablative radiotherapy in the body; however, these are limited to treat just a few lesions in a patient due to the complexity and invasiveness of the necessary motion management techniques. Therefore, patients that present with later stage disease with more than a few metastatic sites (e.g. 5-10 lesions) are not treatable with ablative radiotherapy. RefleXion Medical is developing the first universal method for direct real-time targeting of tumors based on biological guidance. Utilizing positron emission tomography (PET) emissions from the patient, this new technique allows for continuous and automatic dose conformation to multiple lesions, enabling dose escalation to the target(s) and toxicity reduction to sensitive tissues. The concept has been proven with phantom experiments and monte-carlo software simulations. This proposal has two specific aims to mitigate the key risks in the development of the first clinical prototype hardware system. Aim 1 will evaluate the effects that the radiation source or linear accelerator (linac) system may have on the PET system on a bench-top, and vice-versa. Aim 2 will demonstrate simultaneous operation of the linac and PET systems on a closed-ring gantry. Success of these aims will enable the full clinical prototype to be completed and subsequent commercialization of the first biologically guided radiotherapy system.

描述(申请人提供)：消融性放射治疗是一种非常有效的非侵入性破坏肿瘤的方法。然而，体内的肿瘤随着呼吸而移动，需要精确的靶向才能进行这种高剂量的治疗。有多种技术可以实现肿瘤跟踪以实现体内的消融性放射治疗；然而，由于必要的运动管理技术的复杂性和侵袭性，这些技术仅限于治疗患者的少数病变。因此，出现晚期疾病且有多个转移灶(例如5-10个病灶)的患者不能接受消融性放射治疗。Reflexion Medical正在开发第一种基于生物引导的直接实时靶向肿瘤的通用方法。利用患者的正电子发射断层扫描(PET)，这项新技术允许对多个皮损进行连续和自动的剂量确认，使剂量上升到目标(S)，并减少对敏感组织的毒性。这一概念已经通过模体实验和蒙特卡罗软件模拟得到了验证。这项提议有两个具体的目标，以减轻第一个临床原型硬件系统开发中的关键风险。目标1将评估辐射源或直线加速器(直线加速器)系统可能对台式PET系统产生的影响，反之亦然。目标2将演示直线加速器和聚酯系统在闭环式龙门架上的同时运行。这些目标的成功将使完整的临床原型得以完成，并随后实现第一个生物引导放射治疗系统的商业化。